Evidence map›Paper›PMID 29684361›Full record

ArticleThe American journal of pathology2018

High Frequency of Ovarian Cyst Development in Vhl

Yasumichi Kuwahara, Leslie M Kennedy, Anthony N Karnezis, E Lorena Mora-Blanco, Arlin B Rogers, Christopher D Fletcher, David G Huntsman, Charles W M Roberts, W Kimryn Rathmell, Bernard E Weissman

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Yasumichi KuwaharaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Leslie M KennedyLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Anthony N KarnezisDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
E Lorena Mora-BlancoDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Boston and Harvard University, Boston, Massachusetts.
Arlin B RogersLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina.
Christopher D FletcherDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
David G HuntsmanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Charles W M RobertsDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Boston and Harvard University, Boston, Massachusetts.
W Kimryn RathmellLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; Division of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
Bernard E WeissmanLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina. Electronic address: weissman@med.unc.edu.
University of North Carolina at Chapel Hill · USBC Cancer Agency · CAHarvard University · USBrigham and Women's Hospital · US

Funding

Pre-doctoral Training Program in Integrative Vascular BiologyT32HL069768 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Christopher P. Mack · 2002 to 2026
$9.7M
THE FUNCTION OF SNF5 (SMARCB1), AN EPIGENETIC TUMOR SUPPRESSORR01CA113794 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 2005 to 2026
$7.8M
Role of the SWI/SNF complex in tumor suppressionR01CA172152 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 2013 to 2026
$5.1M
The Tumor Suppressor Role of SMARCA4 in SCCOHTR01CA195670 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUNTSMAN, DAVID, TRENT, JEFFREY M. · 2015 to 2019
$3.7M
Role of hsnf5/BAF47 Loss in Human Cancer DevelopmentR01CA091048 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WEISSMAN, BERNARD E. · 2002 to 2012
$2.3M
Chromatin maintenance in cancer progressionR01CA198482 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DAVIS, IAN J, RATHMELL, WENDY KIMRYN · 2015 to 2019
$2.3M
NCI NIH HHS R01 CA091048NCI NIH HHS R01 CA113794NCI NIH HHS R01 CA172152NCI NIH HHS R01 CA195670NCI NIH HHS R01 CA198482NHLBI NIH HHS T32 HL069768
6 · The paper itself

Abstract

The new paradigm of mutations in chromatin-modifying genes as driver events in the development of cancers has proved challenging to resolve the complex influences over disease phenotypes. In particular, impaired activities of members of the SWI/SNF chromatin remodeling complex have appeared in an increasing variety of tumors. Mutations in SNF5, a member of this ubiquitously expressed complex, arise in almost all cases of malignant rhabdoid tumor in the absence of additional genetic alterations. Therefore, we studied how activation of additional oncogenic pathways might shift the phenotype of disease driven by SNF5 loss. With the use of a genetically engineered mouse model, we examined the effects of a hypomorphic Vhl

Indexed as

MutationAnimalsFemaleHemorrhageMiceMice, KnockoutOvarian CystsPhenotypeSMARCB1 ProteinVon Hippel-Lindau Tumor Suppressor ProteinSMARCB1 ProteinSmarcb1 protein, mouseVHL protein, mouseVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID29684361
PMCPMC6024179
OpenAlexW2802605217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.